Millennium Pharmaceuticals wants to be "the" drug company for the new millennium. Operating as Millennium: The Takeda Oncology Company, it's a subsidiary of Japan's Takeda Pharmaceutical. The company's cancer drug Velcade is approved as a treatment for multiple myeloma (a blood cancer) and mantle cell lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). Millennium has more than a dozen other drug candidates in the pipeline, most of them cancer-related. Its oncology-focused sales force, in partnership with Johnson & Johnson, markets the drug, with Millennium handling sales in the US and various J&J subsidiaries handling sales in Europe and most other countries where Velcade is approved.